SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 27, 2020--
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the addition of Jens Holstein to the company’s board of directors and the appointment of Jim Erlinger as executive vice president, general counsel and secretary.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005148/en/
Veracyte Appoints Jens Holstein to Board of Directors (Photo: Business Wire)
“We are thrilled to welcome these two highly accomplished executives to Veracyte,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Jens and Jim each bring extensive life science industry experience and global-market expertise to the company as we prepare to expand our global footprint in 2021. Ultimately, both executives will be invaluable in helping us achieve our vision of delivering our advanced genomic diagnostics tests to physicians and their patients throughout the world on our own distributed instrument platform.”
Mr. Holstein has 25 years of experience in a variety of financial and general management positions at life science and healthcare companies. In 2011, he was appointed chief financial officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany. Before joining MorphoSys, Mr. Holstein worked at pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as regional chief financial officer for the Europe/Middle East Region and as managing director of Fresenius Kabi Deutschland GmbH. Prior to that, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group, including managing director of Fresenius ProServe GmbH, chief financial officer and labor director at Wittgensteiner Kliniken AG, general manager of hospitalia care GmbH, commercial manager of the Projects and Service business unit of Fresenius, and commercial manager of hospitalia international GmbH.
Mr. Erlinger is a seasoned attorney and business executive with 35 years of experience in the life sciences, pharmaceutical, drug development and healthcare industries. Mr. Erlinger previously served as executive vice president, general counsel and secretary of IQVIA (formerly Quintiles), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. At IQVIA, Mr. Erlinger was a member of the Executive Committee and responsible for global legal operations, ethics and compliance, enterprise risk management and quality assurance. Mr. Erlinger spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner.
Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding Veracyte’s ability to deliver genomic diagnostics tests throughout the world on its distributed instrument platform. Forward-looking statements are neither historical facts nor assurances of future performance, but are based only on our current beliefs, expectations and assumptions. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: the impact of COVID-19 on Veracyte’s business and operating results, specifically, and the healthcare system and economy more generally, Veracyte’s ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte’s tests and the applicability of clinical results to actual outcomes; the laws and regulations applicable to Veracyte’s business, including potential regulation by the Food and Drug Administration or other regulatory bodies; Veracyte’s ability to successfully achieve and maintain adoption of and reimbursement for its products; the amount by which use of Veracyte’s products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in Veracyte’s filings with the Securities and Exchange Commission, including the risks set forth in its quarterly report on Form 10-Q for the quarter ended March 31, 2020. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, and the Veracyte logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005148/en/
Investor and Media Contact:
Vice President of Corporate Communications
& Investor Relations
Source: Veracyte, Inc.